ZIVOOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Zivo Bioscience, Inc.
Financials through Q3 FY2025, quarter ended Sep 30, 2025Last filing: 10-Q on Nov 14, 2025
$6.80+0.30 (+4.62%)
Close on Oct 19, 2026
- Market cap
- $25.96M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$5.71 (−45.64%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Zivo Bioscience, Inc. grew revenue 164.5% to $209.03K over the twelve months to Sep 30, 2025.
Revenue
$209.03K
+164.5% vs. a year earlier
Operating income
-$8.46M
TTM Q3 2025
EPS, diluted
-$2.27
TTM Q3 2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2025
Valuation
- Market cap
- $25.96M
- P/E ratio
- –
- Price to sales
- 124.18
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $209.03K
- Net income
- -$8.49M
- EPS, diluted
- -$2.27
- Book value per share
- -$0.86
- Diluted shares
- 4M
Fifteen years at a glance
Fiscal years 2010 to 2024 and trailing twelve months, USD
Revenue
$209.03K+164.5% YoY
Gross profit
$66.21K+153.8% YoY
Operating income
-$8.46M
Net income
-$8.49M
EPS, diluted
-$2.27
Free cash flow
–
Reported periodTrailing twelve months